Akhlaghi Mohammadreza, Dehghani Alireza, Pourmohammadi Reza, Asadpour Leila, Pourazizi Mohsen
Department of Ophthalmology, Isfahan Eye Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
Department of Otolaryngology, Isfahan University of Medical Science, Isfahan, Iran.
J Curr Ophthalmol. 2018 Dec 12;31(2):157-160. doi: 10.1016/j.joco.2018.11.006. eCollection 2019 Jun.
To evaluate the effects of subthreshold diode micropulse laser photocoagulation on treating patients with refractory diabetic macular edema (DME).
This randomized clinical trial recruited patients with DME in both eyes that were resistant to treatment with intravitreal bevacizumab (IVB). The eyes were randomly divided into two groups who received laser therapy and IVB, or IVB alone. Subthreshold diode micropulse laser photocoagulation and IVB injection were administered in one eye, and an IVB injection was administered in the second eye. IVB injections were repeated in both eyes within one month and two months after the first injection. Best corrected visual acuity (BCVA) logarithm of the minimum angle of resolution (logMAR) and central macular thickness (CMT) were measured before, within a month, and three months after start of intervention.
In this study, 42 eyes of 21 patients were evaluated. The mean age of patients was 60.86 ± 8.57 years. Ten patients (47.6%) were male. Within-group analysis showed a significant decreased in BCVA logMAR in the laser + IVB group reflecting improvement in visual acuity (VA) ( < 0.001); it increased in the control group during study reflecting more vision loss ( = 0.01). In the laser + IVB group, a significant decrease in mean ± standard deviation (SD) CMT at 3 months compared to baseline was observed (baseline: 513 ± 126.29 vs. three months: 408.1 ± 95.28; < 0.001). The mean ± SD CMT was significantly lower in the laser + IVB group of eyes than in the control group three months after intervention ( = 0.02).
Using subthreshold diode micropulse laser photocoagulation in combination with IVB can significantly reduce CMT and improve BCVA in patients with refractory DME.
评估阈下二极管微脉冲激光光凝术治疗难治性糖尿病性黄斑水肿(DME)患者的效果。
这项随机临床试验招募了双眼患有DME且对玻璃体内注射贝伐单抗(IVB)治疗耐药的患者。将这些眼睛随机分为两组,一组接受激光治疗联合IVB,另一组仅接受IVB。一只眼睛进行阈下二极管微脉冲激光光凝术并注射IVB,另一只眼睛注射IVB。在首次注射后的1个月和2个月内,双眼均重复注射IVB。在干预开始前、1个月内和3个月后测量最佳矫正视力(BCVA)的最小分辨角对数(logMAR)和中心黄斑厚度(CMT)。
本研究评估了21例患者的42只眼睛。患者的平均年龄为60.86±8.57岁。10例患者(47.6%)为男性。组内分析显示,激光联合IVB组的BCVA logMAR显著降低,反映视力(VA)有所改善(<0.001);在研究期间,对照组的该指标升高,反映视力损失更多(=0.01)。在激光联合IVB组中,与基线相比,3个月时平均±标准差(SD)CMT显著降低(基线:513±126.29,3个月:408.1±95.28;<0.001)。干预3个月后,激光联合IVB组眼睛的平均±SD CMT显著低于对照组(=0.02)。
阈下二极管微脉冲激光光凝术联合IVB可显著降低难治性DME患者的CMT并改善BCVA。